$KZIA

Kazia Therapeutics (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1, 2026, according to the company. Levine has 20+ years in investment banking and biotech finance, most recently as CFO of Cardiff Oncology. Previously, he was CFO of Cidara Therapeutics and led major licensing deals, and earlier held roles at Goldman Sachs. The move supports Kazia’s advancement of paxalisib and pipeline milestones.

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. The company plans to increase enrollment from 12 to 36 patients, citing continued safety, tolerability and early clinical activity. It aims to further assess dose optimization and preliminary efficacy with pembrolizumab and chemotherapy, and expects updates through 2026–2027.

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity. The larger dataset is expected to better assess ORR, PFS and biomarkers, with updates anticipated through 2026–2027.

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care in advanced triple-negative breast cancer, increasing planned enrollment from 12 to 36 patients. The company cited continued safety, tolerability and early clinical activity, aiming to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy.

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity, to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy. Updates are expected through 2026-2027.

Kazia Therapeutics (NASDAQ: KZIA) said it will expand its ongoing Phase 1b trial of paxalisib plus standard-of-care therapy in advanced triple-negative breast cancer. Planned enrollment will rise from 12 to 36 patients, based on continued safety, tolerability and early clinical activity. The larger dataset is expected to better assess ORR, PFS and biomarkers with pembrolizumab and chemotherapy.

Kazia Therapeutics Limited (NASDAQ:KZIA) has announced it has regained compliance with Nasdaq listing standards. This development led to the cancellation of a previously scheduled hearing before the Nasdaq Hearings Panel for January 8, 2026. The company met the alternative minimum stockholders’ equity requirement, and its American Depositary Shares will continue to be listed on the Nasdaq Capital Market.

First patient saw over 50% drop in CTCs and reduced cluster formation after 21 days of treatment. Phase 1b trial continues enrollment to study safety, immune impact, and long-term tumor response. Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest ...

Kazia on Wednesday announced positive preclinical data for its paxalisib drug in triple-negative breast cancer. The company's stock is soaring over 77% on exceptionally high and unusual trading volume. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre on ...